Skip to main content

Advertisement

SpringerLink
Log in

Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation

  • Editorial
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026

    Article  CAS  PubMed  Google Scholar 

  2. Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890–899

    Article  CAS  PubMed  Google Scholar 

  3. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468

    Article  CAS  PubMed  Google Scholar 

  4. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, WHO, Geneva

  5. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7:390–406

    CAS  PubMed  Google Scholar 

  6. Compston JE, Papapoulos SE, Blanchard F (1998) Report on osteoporosis in the European Community: current status and recommendations for the future. Working Party from European Union Member States. Osteoporos Int 8:531–534

    Article  CAS  PubMed  Google Scholar 

  7. National Osteoporosis Foundation (1998) Physicians guide to prevention and treatment of osteoporosis, Washington, DC

  8. National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 8 [Suppl 4]:S7–80

  9. U.S. Preventive Services Task Force (2002) Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 137:526–528

    PubMed  Google Scholar 

  10. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW Jr (2004) Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab 89:3651–3655

    Article  CAS  PubMed  Google Scholar 

  11. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258

    Article  CAS  PubMed  Google Scholar 

  12. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11 [Suppl 6]:S2–17

  13. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739

    CAS  PubMed  Google Scholar 

  14. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936

    Article  PubMed  Google Scholar 

  15. Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11:192–202

    Article  CAS  PubMed  Google Scholar 

  16. Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B (2004) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int (DOI 10.1007/s00198-004-1623-4; this issue)

    Google Scholar 

  17. Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B (2004) Intervention thresholds for osteoporosis in men and women. Bone (in press)

  18. Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. Bmj 323:1300–1303

    Article  CAS  PubMed  Google Scholar 

  19. Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2004) Cost-effectiveness of raloxifene in the UK—An economic evaluation based on the MORE-study. Osteoporos Int (DOI 10.1007/s00198-004-1688-0; this issue)

  20. Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY (2002) The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 13:1–5

    Article  CAS  PubMed  Google Scholar 

  21. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541

    Article  CAS  PubMed  Google Scholar 

  22. Chesnut CH, 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267–276

    Article  CAS  PubMed  Google Scholar 

  23. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645

    Article  CAS  PubMed  Google Scholar 

  24. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352

    Article  CAS  PubMed  Google Scholar 

  25. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91

    Article  CAS  PubMed  Google Scholar 

  26. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  PubMed  Google Scholar 

  27. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082

    Article  CAS  PubMed  Google Scholar 

  28. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan Ge-H, Reda C, Yates AJ, Ravn P (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 128:253–261

    CAS  PubMed  Google Scholar 

  29. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995

    Article  CAS  PubMed  Google Scholar 

  30. Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method of setting intervention threshold. Osteoporos Int 12:417–427

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Claude Bernard University of Lyon and INSERM Research Unit 403, Lyon, France

    Pierre D. Delmas

  2. University of Geneva, Geneva, Switzerland

    René Rizzoli

  3. University of Southampton, Southampton, UK

    Cyrus Cooper

  4. University of Liège, Belgium

    Jean-Yves Reginster

  5. Pavillon F, Hôpital E. Herriot, 5 Place d’Arsonval, 69437, Lyon Cedex 03, France

    Pierre D. Delmas

Authors
  1. Pierre D. Delmas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. René Rizzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cyrus Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Yves Reginster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre D. Delmas.

Additional information

P.D. Delmas is president of the International Osteoporosis Foundation (IOF); R. Rizzoli is chairman of the IOF Committee of Scientific Advisors; C. Cooper and J.-Y. Reginster are members of the IOF Committee of Scientific Advisors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Delmas, P.D., Rizzoli, R., Cooper, C. et al. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 16, 1–5 (2005). https://doi.org/10.1007/s00198-004-1813-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-004-1813-0

Keywords

Search

Navigation